Genmab A/S (GMAB) Projected to Release Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $0.37 per share and revenue of $1.1110 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 12:00 PM ET.

Genmab A/S Trading Down 0.7%

Shares of NASDAQ GMAB opened at $28.68 on Tuesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. Genmab A/S has a 52-week low of $21.00 and a 52-week high of $35.43. The firm has a 50 day moving average price of $27.07 and a two-hundred day moving average price of $28.08. The stock has a market cap of $17.88 billion, a P/E ratio of 21.73, a price-to-earnings-growth ratio of 1.81 and a beta of 0.83.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. TD Cowen raised Genmab A/S from a “hold” rating to a “buy” rating and raised their target price for the stock from $32.00 to $43.00 in a research report on Wednesday, July 22nd. Truist Financial started coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price target on the stock. New Street Research set a $43.00 price objective on Genmab A/S in a research report on Wednesday, July 22nd. Weiss Ratings raised Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. Finally, BNP Paribas Exane upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.28.

Institutional Trading of Genmab A/S

A number of large investors have recently bought and sold shares of GMAB. CIBC Private Wealth Group LLC lifted its stake in shares of Genmab A/S by 291.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after purchasing an additional 616 shares during the period. Osaic Holdings Inc. boosted its holdings in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of Genmab A/S by 1,229.0% during the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after buying an additional 1,143 shares during the period. Brown Brothers Harriman & Co. grew its position in shares of Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after buying an additional 780 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after acquiring an additional 1,174 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.